298380 — ABL Bio Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual income statement for ABL Bio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,104	5,332	67,301	65,547	33,403
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	67,751	57,637	63,801	68,164	92,780
Operating Profit	-59,647	-52,305	3,500	-2,617	-59,377
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-55,606	-43,558	3,209	-2,647	-55,529
Provision for Income Taxes
Net Income After Taxes	-55,606	-43,558	3,209	-2,647	-55,529
Net Income Before Extraordinary Items
Net Income	-55,606	-43,558	3,209	-2,647	-55,529
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-55,606	-43,558	3,209	-2,647	-55,529
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1,207	-927	12	-55.3	-1,156
Dividends per Share